<DOC>
	<DOCNO>NCT00918229</DOCNO>
	<brief_summary>Primary Goal The study 's primary goal ass safety BioProtect biodegradable balloon implant implantation procedure , prostate cancer subject undergoing routine radiation therapy ( XRT ) treatment . Safety BioProtect device assess report adverse event . Secondary Goal The study 's secondary goal evaluate effectiveness BioProtect biodegradable balloon implant prostate cancer subject undergoing routine XRT treatment . Effectiveness assess term increase distance anterior rectal wall prostate noticeable reduction isodose rectum .</brief_summary>
	<brief_title>Study Assess Safety Efficacy BioProtect Balloon Prostate Cancer Subjects</brief_title>
	<detailed_description>Primary Endpoint Parameters The incidence unexpected serious adverse event related BioProtect 's SpaceGuard balloon implant and/or implantation procedure : 1 . Serious Adverse Events related BioProtect balloon and/or implantation procedure . Serious adverse event define adverse requiring operation and/or associate prolongation hospital stay . Serious Adverse Events document Serious Adverse Event Form . 2 . Adverse Events related BioProtect balloon and/or implantation procedure . Adverse Events document Adverse Event Form . 3 . Subjective discomfort relate balloon implantation procedure assess pain analogue scale . Secondary Endpoint Parameters A 10 % decrease great average rectal dos V50 least 75 % subject balloon implantation compare dos V50 balloon implantation . This measured routine Dose Volume Histogram ( DVH ) per local hospital practice accord instruction regard anatomical landmark delineate protocol .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Adult male 45 year old less 85 . Diagnosed locally confine prostate cancer per hospital practice definition local confine prostate cancer . Subject schedule localized prostate XRT treatment Zubrod performance status 01 ; Karnofsy &gt; 80 Blood CBC biochemistry two week screen demonstrating : Platelets ≥ 100,000 cells/mm3 Hemoglobin ≥ 10.0 g/dl Normal value electrolyte ( sodium , potassium , calcium ) Normal value PT , PTT INR test . Peak Uroflow rate ≥ 13ml/sec Residual Urine volume Test result &lt; 150 ml Urinalysis ( RBC , WBC ) urine culture Subject able comprehend give inform consent participation study consider investigator good compliance study . Any prior prostate resection compliant prostate urethra assess transrectal ultrasound ( TRUS ) Prior radical prostatectomy Prior cryosurgery radiotherapy prostate cancer , local therapy prostate cancer Suspected extension prostate tumour toward rectum evidence acceptable imaging modality use study site Prior surgical procedure involve perirectal periprostatic area Prior radiotherapy pelvis , include brachytherapy body organ Unstable angina Congestive heart failure ( CHF ) phase III IV CHF require hospitalization within last 6 month prior screen Transmural myocardial ( MI ) infarction within last 6 month prior screen Moderate severe respiratory failure , hepatic failure renal failure Acute infection require intravenous antibiotic time screen Uncontrolled bleed disorder Uncontrolled diabetes mellitus Known HIV positive immunosuppressive disorder Inflammatory diseases perineal skin Urinary tract infection acute chronic prostatitis Uncontrolled moderate severe urinary disorder Active inflammatory bowel disease moderate severe gastrointestinal ( GI ) disorder Known suspected rectal carcinoma Subjects anterior resection rectum rectal amputation Concurrent participation clinical study Intraoperative exclusion criterion : Irregular finding implant physician implantation best implant physician may lead prostate compliance lead urinary retention symptom .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Prostate</keyword>
	<keyword>cancer</keyword>
	<keyword>radiation</keyword>
	<keyword>biodegradable implantable balloon</keyword>
	<keyword>intrarectal balloon</keyword>
</DOC>